Leadership & Pay ·
Arcutis Biotherapeutics appoints former AbbVie CMO Robert Scott to its Board
ARQTArcutis Biotherapeutics, Inc.
The Arcutis Biotherapeutics board increased the authorized number of directors from ten to eleven and appointed Dr. Robert Scott as a Class II director effective October 23, 2026. Dr. Scott joins the Nominating and Corporate Governance Committee and receives an initial stock option award for 20,507 shares plus prorated annual equity valued at approximately $350,000 and cash retainers totaling $55,000. He brings over four decades of pharmaceutical leadership experience, including tenure as Chief Medical Officer at AbbVie and roles at Amgen and Pfizer. Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing treatments for chronic inflammatory skin diseases.